Table 3.
Evidence-based efficacy of biological and targeted synthetic DMARDs in different SpA manifestations
| AS/axSpA | (polyarticular) PsA | pSpA | |
|---|---|---|---|
| TNFi | Yes | Yes | Yes |
| IL-17i | Yes | Yes | ? |
| IL-12/23i | No | Yes | ? |
| JAKi | Yes | Yes | ? |
| PDE4i | No | Yes | ? |
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; DMARDs, disease-modifying antirheumatic drugs; IL-17i, interleukin-17 inhibitor; IL-12/23i, interleukin-12/23 inhibitor; JAKi, Janus kinase inhibitor; PDE4i, phosphodiesterase-4 inhibitor; pSpA, peripheral spondyloarthritis; PsA, psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.